Skip to main content
Equibles
TEVA logo

TEVA · Teva Pharmaceutical Industries Ltd · Investor Relations

Track TEVA — free

Use TEVA with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research TEVA.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$39.09 -0.51 (-1.29%)
Rebalance outlook locked
Market Cap
$45.67B
Shares
1.17B
Volume · Oct 1 389.79K Avg daily vol (3M) 5.31M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Upcoming events

Date Event Type
2026-11-03 13:00 UTC Q3 2026 Teva Pharmaceutical Industries Ltd. Earnings Conference Call Earnings call

Recent news

Date Headline
2026-10-01 Samsung Bioepis and Teva Expand Strategic Partnership to Advance Up to Six Potential Biosimilar Candidates
2026-09-30 TAPI (Technology & API Services) Names Serge Rogasik CEO to lead next chapter of growth and competitiveness
2026-09-28 Teva Continues Biosimilar Momentum with U.S. FDA Approval of DEGEVMA™ (denosumab-adet), a Biosimilar to Xgeva® (denosumab)
2026-09-23 Teva to Host Conference Call to Discuss Third Quarter 2026 Financial Results on November 3, 2026 at 8 a.m. ET
2026-09-23 Teva Releases Q3 2026 Aide Memoire
2026-09-18 New Teva Study Identifies the Attributes that Healthcare Providers Prioritize when Selecting a Treatment for Tardive Dyskinesia in Older Patients
2026-09-18 Teva Highlights New Real-World Data Showing UZEDY® (risperidone) Outperforms Other Long-Acting Injectables in Keeping Schizophrenia Patients on Treatment, While Reducing Emergency Care and Healthcare Costs
2026-09-18 Teva Announces New Olanzapine LAI (TEV-'749) Post Hoc Data Highlighting High Rates of Stabilization and Long-Term Efficacy as Once-Monthly Subcutaneous Injectable for the Treatment of Schizophrenia in Adults
2026-09-16 Teva Launches LongActingImpact.com to Advance Understanding of Earlier, Effective and Uninterrupted Schizophrenia Care
2026-09-14 Teva Begins Trading Ordinary Shares Directly on the NYSE, Marking a Milestone in its Pivot to Growth Strategy
2026-09-10 Teva Announces Successful Pricing of $4.9 billion (Equivalent) Senior Notes
2026-09-07 Teva Announces Launch of Offering of Senior Notes
2026-09-04 S&P Global Ratings Upgrades Teva to BBB-, Marking Third Credit Rating Upgrade in Recent Months and Reflecting Strong Execution and Financial Discipline
2026-09-02 Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential
2026-09-01 Teva to Present at Morgan Stanley, J.P. Morgan and BofA Investor Conferences in September
2026-08-31 Teva and Trump Administration Announce Intent to Reach Agreement around Affordable Medicines and Supply Chain Security for Patients in the U.S.
2026-08-28 Teva Announces Proposed Acquisition of a Novel Neuroscience Product Reinforcing Disciplined Business Development Approach Under Pivot to Growth Strategy
2026-08-19 U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
2026-08-11 Moody’s Ratings Upgrades Teva to Investment Grade, Reflecting the Ongoing Execution of Pivot to Growth Strategy
2026-07-29 Teva Delivers Strong Q2 Results and Raises Outlook for All Three Key Innovative Brands, Reflecting Continued Execution of Its Pivot to Growth Strategy
2026-07-09 Teva and Polpharma Biologics Announce Global Licensing Agreement for a Biosimilar Candidate to Ocrevus® (ocrelizumab) for Multiple Sclerosis
2026-07-07 Teva to Advance Its Anti-IL-15 Antibody, Designed for Quarterly Dosing, Into Phase 2b Development in Vitiligo, Following Encouraging Phase 1b Results
2026-06-18 Teva Releases Q2 2026 Aide Memoire
2026-06-18 Teva Submits NDA for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Tourette Syndrome
2026-06-18 Teva to Host Conference Call to Discuss Second Quarter 2026 Financial Results on July 29, 2026 at 8 a.m. ET

Past events

Date Event Type
2026-09-23 BofA Global Healthcare Conference 2026 Conference
2026-09-22 JPM U.S. All Stars Conference Conference
2026-09-22 J.P. Morgan U.S. All Stars Conference Conference
2026-09-14 Morgan Stanley 24th Annual Global Healthcare Conference Conference
2026-09-02 IL-15 Celiac Disease Phase 2a Topline Results - Conference Call Earnings call
2026-07-29 Q2 2026 Teva Pharmaceutical Industries Ltd. Earnings Conference Call Earnings call
2026-07-07 IL-15 Vitiligo Phase 1b 24 Week Efficacy Results - Conference Call Earnings call
2026-06-08 Goldman Sachs Global Healthcare Conference Conference
2026-05-12 BofA Securities Health Care Conference Conference
2026-04-29 Q1 2026 Teva Pharmaceutical Industries Ltd. Earnings Conference Call Earnings call
2026-03-10 Barclays 28th Annual Global Healthcare Conference Conference
2026-03-09 Leerink Partners Global Healthcare Conference Conference
2026-03-03 UBS European Healthcare Conference Conference
2026-02-17 Duvakitug IBD Ph2b Maintenance Top-Line Result Event
2026-01-28 Q4 2025 Teva Pharmaceutical Industries Ltd. Earnings Conference Call Earnings call
2026-01-13 44th Annual J.P. Morgan Healthcare Conference Conference
2025-12-04 Citi's 2025 Global Healthcare Conference Conference
2025-12-03 Piper Sandler 37th Annual Healthcare Conference Conference
2025-12-03 8th Annual Evercore Healthcare Conference Conference
2025-11-18 Jefferies London Healthcare Conference Conference
2025-11-10 UBS Global Healthcare Conference Conference
2025-11-05 Q3 2025 Teva Pharmaceutical Industries Ltd. Earnings Conference Call Earnings call
2025-09-24 BofA - 2025 Global Healthcare Conference Conference
2025-09-22 Olanzapine LAI (TEV-‘749) Phase 3 SOLARIS Data Presentation – Conference Call Conference
2025-09-09 Morgan Stanley 23rd Annual Global Healthcare Conference Conference

Source: https://ir.tevapharm.com/

Key facts CIK 818686 CUSIP 881624209 13F (30d) 15 filings 13 filers Visit website Investor relations